NIPT triSure **

Preeclampsia is a high blood pressure (hypertension) disorder that can occur after the 20th week of pregnancy. Complications of preeclampsia may include: fetal growth restriction, preterm birth, and placental abruption. PlGF assay, in conjunction with sFlt-1 assay, other diagnostic tests, and clinical information, is for use in diagnosing preeclampsia.

NIPT First is a type of NIPT (Non-Invasive Prenatal Testing) which is a pregnancy screening test. It detects potential congenital defects caused by chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The test examines small fragments of fetal DNA in the mother’s blood to assess the risk of these chromosomal anomalies. This provides important information for expectant parents and healthcare providers about the fetus’s health. It’s a non-invasive option, which minimizes risks to both the mother and fetus, while offering early insights into potential genetic concerns.

Our semen analysis uses the new FDA-certified automated semen analysis system, SQA-IQ. The evaluation criteria are based on the latest WHO 6th Edition for Human Semen guidelines. This test determines male fertility status based on testing semen samples. Blood tests also need to be done to comprehensively analyse male infertility.

The test measures a hormone called hCG, produced during pregnancy by the placenta and found in the blood and urine. Testing for hCG can be done as early as ten days after conception to determine if you are pregnant. Measuring hCG can also help identify potential complications.